A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma

European Urology - Netherlands
doi 10.1016/j.eururo.2012.06.043
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Elsevier BV

Related search

Safety and Efficacy of Sunitinib for Advanced Non-Clear Cell Renal Cell Carcinoma

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2015English

Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial

Oncologist
Cancer ResearchMedicineOncology
2015English

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Clinical Cancer Research
Cancer ResearchOncology
2018English

A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2014English

Sphingosine Kinase 1 Overexpression Contributes to Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

OncoImmunology
OncologyAllergyImmunology
2018English

A Phase II Trial of Sunitinib in Patients With Renal Cell Cancer and Untreated Brain Metastases

Clinical Genitourinary Cancer
OncologyUrology
2014English

Prognostic Value of Granulocyte Colony-Stimulating Factor in Patients With Non-Metastatic Clear Cell Renal Cell Carcinoma

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy